Fate Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 38 U.S.-traded ETFs. FATE has around 5.7M shares in the U.S. ETF market. The largest ETF holder of FATE is the SPDR S&P Biotech ETF (XBI), with approximately 1.52M shares. Investors may also find of interest that the ETF with the largest allocation to FATE stock is Loncar Cancer Immunotherapy ETF (CNCR), with a portfolio weight of 2.66%. On average, U.S. ETFs allocate 0.23% of FATE to their portfolios.
Additionally, FATE is a favorite stock for Vanilla and Equal ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with FATE as a holding is the ALPS Medical Breakthroughs ETF (SBIO), with a return of 19.89%.